104 related articles for article (PubMed ID: 1580288)
21. A double blind comparison of perindopril and atenolol in essential hypertension.
Thurston H; Mimran A; Zanchetti A; Creytens G; Rorive G; Brown CL; Santoni JP
J Hum Hypertens; 1990 Oct; 4(5):547-52. PubMed ID: 2283644
[TBL] [Abstract][Full Text] [Related]
22. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
[TBL] [Abstract][Full Text] [Related]
23. Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty?
Plouin PF; Battaglia C; Alhenc-Gélas F; Corvol P
Am J Hypertens; 1991 Apr; 4(4 Pt 1):356-62. PubMed ID: 2059395
[TBL] [Abstract][Full Text] [Related]
24. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group.
Overlack A; Adamczak M; Bachmann W; Bönner G; Bretzel RG; Derichs R; Krone W; Lederle RM; Reimann HJ; Zschiedrich H
Am J Med; 1994 Aug; 97(2):126-34. PubMed ID: 8059778
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin converting enzyme inhibition, pulse wave velocity and ambulatory blood pressure measurements in essential hypertension.
Santoni JP; Asmar R; Safar ME
Clin Exp Hypertens A; 1989; 11 Suppl 2():535-44. PubMed ID: 2691127
[TBL] [Abstract][Full Text] [Related]
26. Renal function, glycaemic control and perindopril in diabetic patients.
Brichard S; Ketelslegers JM; Lambert AE
Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():57-61. PubMed ID: 2505714
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin converting enzyme inhibition decreases systolic blood pressure more than diastolic pressure as shown by ambulatory blood pressure monitoring.
Asmar RG; Pannier BM; Santoni JP; Safar ME
J Hypertens Suppl; 1988 Dec; 6(3):S79-81. PubMed ID: 3225692
[TBL] [Abstract][Full Text] [Related]
28. The effect of perindopril on blood pressure in humans on different sodium intakes.
Morgan T; Anderson A; Wilson D; Murphy J; Nowson C
J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S116-8. PubMed ID: 2485043
[TBL] [Abstract][Full Text] [Related]
29. Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients.
Vaur L; Bobrie G; Dutrey-Dupagne C; Dubroca I; Vaisse B; d'Yvoire MB; Elkik F; Chatellier G; Menard J
Am J Hypertens; 1998 Feb; 11(2):165-73. PubMed ID: 9524044
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin-converting enzyme inhibition in mild hypertension with concomitant diseases and therapies: an efficacy, safety, and compatibility study of novel design, the Perindopril Therapeutic Safety Study.
Stumpe KO; Overlack A
Am J Med; 1992 Apr; 92(4B):98S-101S. PubMed ID: 1580290
[TBL] [Abstract][Full Text] [Related]
31. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA
Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
[TBL] [Abstract][Full Text] [Related]
32. Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. The Perindopril Study Group.
Chrysant SG; McDonald RH; Wright JT; Barden PL; Weiss RJ
Clin Pharmacol Ther; 1993 Apr; 53(4):479-84. PubMed ID: 8477565
[TBL] [Abstract][Full Text] [Related]
33. The safety and acceptability of perindopril.
Brown CL
J Hum Hypertens; 1990 Oct; 4 Suppl 4():51-5; discussion 55-6. PubMed ID: 2283654
[TBL] [Abstract][Full Text] [Related]
34. [24-hour effectiveness and tolerance of perindopril (Prestarium), an ACE inhibitor, in the treatment of mild to moderate hypertension. A 1-year Czech and Slovak study].
Widimský J; Fedelesová V; Uhlír O
Vnitr Lek; 1995 Jul; 41(7):441-4. PubMed ID: 7571476
[TBL] [Abstract][Full Text] [Related]
35. Enhanced brachial artery compliance following perindopril in essential hypertension.
Asmar RG; Safar ME; Santoni JP; Pannier BM; London GM
Am J Hypertens; 1988 Jul; 1(3 Pt 3):103S-105S. PubMed ID: 3415779
[TBL] [Abstract][Full Text] [Related]
36. Management of moderate to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantation.
Grekas D; Dioudis C; Kalevrosoglou I; Papoulidou F; Goutsaridis N; Alivanis P; Tourkantonis A
Clin Nephrol; 1995 Nov; 44(5):299-302. PubMed ID: 8605709
[TBL] [Abstract][Full Text] [Related]
37. Perindopril versus captopril: efficacy and acceptability in an Italian multicenter trial.
Agabiti-Rosei E; Ambrosioni E; Finardi G; Folino P; Gambassi G; Malini P; Marchesi E; Muiesan ML; Semplicini A; Pessina AC
Am J Med; 1992 Apr; 92(4B):79S-83S. PubMed ID: 1580285
[TBL] [Abstract][Full Text] [Related]
38. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients.
Fogari R; Mugellini A; Zoppi A; Corradi L; Preti P; Lazzari P; Derosa G
Am J Hypertens; 2002 Apr; 15(4 Pt 1):316-20. PubMed ID: 11991216
[TBL] [Abstract][Full Text] [Related]
39. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension.
Asmar RG; Journo HJ; Lacolley PJ; Santoni JP; Billaud E; Levy BI; Safar ME
J Hypertens Suppl; 1988 Dec; 6(3):S33-9. PubMed ID: 3225688
[TBL] [Abstract][Full Text] [Related]
40. Further evidence that chronic perindopril treatment maintains neurohormonal suppression but does not lower blood pressure in chronic cardiac failure.
MacFadyen RJ; Barr CS; Sturrock ND; Fenwick M; Struthers AD
Br J Clin Pharmacol; 1997 Jul; 44(1):69-76. PubMed ID: 9241099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
